initial public offerings (IPOs) trading on American exchanges

Thursday, September 4, 2014

Pfenex (PFNX) began trading on the NYSE on 24 July 2014

William Blair & Company LLC and JMP Securities LLC are joint book-running managers.Mizuho Securities USA Inc. is co-manager.


Pfenex Inc. is a clinical-stage biotechnology company. The Company engaged in the development of difficult to manufacture and proteins, initially focused on biosimilar therapeutics (biosimilars). The Company’s product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).


10790 Roselle St
SAN DIEGO, CA 92121-1508
United States 

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin-60.28%-34.09%
Operating margin-59.54%-56.21%
EBITD margin--47.56%
Return on average assets-19.92%-12.55%
Return on average equity--

No comments:

Post a Comment